AIDS 2026 Brings Zero HIV Infections and a Funding Emergency

A Rio conference hall, a Michigan dental clinic, and a Texas grocery store audit gave Wednesday's health desk both cause for hope and reason for alarm in equal measure.

Tuesday, 29 July — Silver Diamine Fluoride Defeats Cavities in 830 Children Without Drilling

Dentists in Japan, Australia, and much of Latin America have used silver diamine fluoride (SDF) to halt childhood tooth decay for decades, but the United States lacked the large-scale randomised evidence required to approve it as a therapeutic drug. That evidence arrived Tuesday in JAMA Pediatrics, where researchers from the University of Michigan — working with Head Start and Early Head Start programmes across Michigan, New York, and Iowa — published results from a Phase III randomised controlled trial of 830 children younger than six. A 38% SDF solution, brushed onto decaying primary teeth every six months, arrested the progression of decay in more than half of affected teeth — with no injections, no drilling, and no sedation. Treatment takes seconds per tooth. The only notable side effect is permanent darkening of the treated area, which some families find cosmetically undesirable. Safety was confirmed even in children as young as one year old. Scientists at the University of Michigan described the findings as potentially practice-changing for early-childhood programmes where paediatric dental access is scarce and sedation procedures are costly. For families in underserved communities — including those across Cyprus and the eastern Mediterranean where rural dental infrastructure is stretched — a brush-on option that a trained nurse or health worker can administer during a well-child visit represents a practical, low-cost advance.

Sunday, 27 July — AIDS 2026, Rio: Lenacapavir Shows Zero New HIV Infections in Open-Label Extension

At the 26th International AIDS Conference in Rio de Janeiro (27–31 July), Gilead Sciences presented long-awaited open-label extension data from the PURPOSE 1 trial of lenacapavir for HIV prevention. The headline result: across 4,493 person-years of observation in the extension phase, zero participants who received the twice-yearly subcutaneous injection acquired HIV. Injection adherence remained high — 92 to 96% across both PURPOSE trials — suggesting the twice-yearly schedule is practical in real-world settings. Lenacapavir is a first-in-class HIV capsid inhibitor that works by blocking multiple stages of the HIV replication cycle simultaneously; as pre-exposure prophylaxis (PrEP), two injections per year replace the significant daily pill burden that many patients find difficult to sustain. The drug is approved in several high-income countries, and Gilead has announced tiered pricing commitments for lower-income settings. Full Phase 3 results from the ISLEND trial — evaluating a long-acting oral single-tablet HIV treatment combination — were also presented at the conference.

Sunday, 27 July — AIDS 2026, Rio: Global HIV Funding at Its Lowest Level in Nearly Two Decades

The scientific celebration around lenacapavir's zero-infection data was tempered on the same day by a UNAIDS special report documenting an accelerating funding crisis in the global HIV response. International HIV financing fell 18% to $7.3 billion in 2025 — the lowest level since 2007. The United States, which has historically contributed roughly 75% of international HIV funding, cut its bilateral spending by 28%, from $5.4 billion in 2024 to $3.9 billion in 2025. The practical consequences are already measurable: condom availability has been reduced by more than 90% in some countries; community-led outreach services that reach the populations most vulnerable to HIV have lost personnel and supply chains; PEPFAR disruptions have interrupted antiretroviral treatment for hundreds of thousands of patients. In 2025, 1.2 million new HIV infections were recorded — new infections are rising in 21 countries and three WHO regions — and 570,000 people died of AIDS-related illness. UNAIDS projects that, without a course correction, more than three million people could acquire HIV by 2030. "Without renewed commitment and action," the report states, "the world risks a resurgence of the HIV epidemic." The parallel headlines from AIDS 2026 — a prevention injection that produces zero infections and a funding architecture that is actively retreating — define the conference's central tension.

Saturday, 26 July — NUTRITION 2026: Four in Five Packaged Toddler Foods Are Ultra-Processed

An audit presented this week at NUTRITION 2026 — the annual meeting of the American Society for Nutrition in National Harbor, Maryland — found that 81% of 2,783 packaged infant and toddler food products examined across 21 grocery stores in Austin, Texas met the Nova classification for ultra-processed food. Almost half (49%) of all products failed to meet at least one nutritional threshold set by the World Health Organisation's Nutrition and Promotion Profile Model for commercial foods designed for children aged six to thirty-six months. Researchers at the University of Texas at Austin systematically photographed baby and toddler aisles — excluding infant formula, beverages, and first-stage purees — and assessed full nutrient labels. Ultra-processed products were significantly more likely to contain high levels of added sugar than their less-processed counterparts. The study is confined to a single US city, which limits direct generalisation, but the pattern it documents is consistent with similar audits conducted in Europe, Latin America, and Australia. The findings reinforce concern that the commercial toddler food market is not structured to support the nutritional guidance that paediatricians and public health bodies recommend, and that caregivers cannot rely on marketing claims of health or suitability when choosing packaged foods for young children.

Monday, 28 July — FDA Approves Gwyn Lo, a Once-Weekly Hormonal Contraceptive Patch

The US Food and Drug Administration approved Gwyn Lo (ethinyl estradiol and norelgestromin) from Viatris on 28 July — a once-weekly combination hormonal contraceptive transdermal patch indicated for the prevention of pregnancy. The patch is applied to the skin once a week and replaced on the same day the following week. Hormonal patches work by releasing oestrogen and progestin transdermally into the bloodstream, suppressing ovulation and thickening cervical mucus; the mechanism is well established and carries a strong safety and efficacy record in combination hormonal contraception. Adherence research consistently shows that weekly dosing regimens improve real-world coverage rates for many patients compared with daily oral pill schedules. Gwyn Lo carries an updated dosing profile relative to the original weekly patch (Ortho Evra, first approved in 2001). Viatris expects to confirm commercial availability in the United States after Drug Enforcement Administration scheduling is completed.

---

The content in this roundup is journalistic in nature and does not constitute medical advice. Readers should consult a qualified clinician or pharmacist before making any changes to their treatment, medication, or healthcare routines.